Novel fluoroquinolones analogues bearing 4-(arylcarbamoyl)benzyl: design, synthesis, and antibacterial evaluation.

[1]  R. Razo‐Hernández,et al.  Novel ciprofloxacin and norfloxacin-tetrazole hybrids as potential antibacterial and antiviral agents: Targeting S. aureus topoisomerase and SARS-CoV-2-MPro , 2022, Journal of Molecular Structure.

[2]  H. Kaur,et al.  Quinoline derivatives volunteering against antimicrobial resistance: rational approaches, design strategies, structure activity relationship and mechanistic insights , 2022, Molecular Diversity.

[3]  S. Abbas,et al.  Synthesis and molecular docking of new N4-piperazinyl ciprofloxacin hybrids as antimicrobial DNA gyrase inhibitors , 2022, Molecular Diversity.

[4]  Katarina Cirnski,et al.  Novel fluoroquinolone hybrids as dual DNA gyrase and urease inhibitors with potential antibacterial activity: Design, synthesis, and biological evaluation , 2022, Journal of Molecular Structure.

[5]  Yi Tan,et al.  Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents. , 2022, Bioorganic & medicinal chemistry letters.

[6]  Ping Yang,et al.  Synthesis and in vitro antibacterial activity of N-acylarylhydrazone-ciprofloxacin hybrids as novel fluoroquinolone derivatives , 2022, Journal of Molecular Structure.

[7]  O. Temiz-Arpaci,et al.  Synthesis, quantum mechanical calculations, antimicrobial activities and molecular docking studies of five novel 2,5-disubstituted benzoxazole derivatives , 2021 .

[8]  Hanan H. Georgey,et al.  Design and synthesis of ciprofloxacin-sulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects , 2021, European Journal of Medicinal Chemistry.

[9]  Mai E. Shoman,et al.  Thiazolidine-2,4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities , 2021, Molecular Diversity.

[10]  Naveen Kuntala,et al.  Novel heterocyclic 1,3,4-oxadiazole derivatives of fluoroquinolones as a potent antibacterial agent: Synthesis and computational molecular modeling , 2021, Molecular Diversity.

[11]  A. Foroumadi,et al.  Design, synthesis, molecular docking study, and antibacterial evaluation of some new fluoroquinolone analogues bearing a quinazolinone moiety , 2020, DARU Journal of Pharmaceutical Sciences.

[12]  Cai-Guang Yang,et al.  Design and synthesis of novel desfluoroquinolone-aminopyrimidine hybrids as potent anti-MRSA agents with low hERG activity. , 2020, Bioorganic chemistry.

[13]  Riham F. George,et al.  Design, synthesis, antimicrobial, and DNA gyrase inhibitory properties of fluoroquinolone–dichloroacetic acid hybrids , 2020, Chemical biology & drug design.

[14]  M. Chifiriuc,et al.  Design, Synthesis and Biological Evaluation of New Piperazin-4-yl-(acetyl-thiazolidine-2,4-dione) Norfloxacin Analogues as Antimicrobial Agents , 2019, Molecules.

[15]  Ebrahim Soleimani,et al.  Ciprofloxacin-functionalized magnetic silica nanoparticles: as a reusable catalyst for the synthesis of 1H-chromeno[2,3-d]pyrimidine-5-carboxamides and imidazo[1,2-a]pyridines , 2019, Molecular Diversity.

[16]  N. Jain,et al.  Synthesis of novel tetrazole containing hybrid ciprofloxacin and pipemidic acid analogues and preliminary biological evaluation of their antibacterial and antiproliferative activity , 2018, Molecular Diversity.

[17]  M. Balouiri,et al.  Methods for in vitro evaluating antimicrobial activity: A review☆ , 2015, Journal of pharmaceutical analysis.

[18]  Ankit Jain,et al.  Synthesis and antibacterial evaluation of novel analogs of fluoroquinolones annulated with 6-substituted-2-aminobenzothiazoles , 2015 .

[19]  L. Piddock,et al.  Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. , 2014, Trends in microbiology.

[20]  N. Jawali,et al.  Importance of chemical modification at C-7 position of quinolones for glutathione-mediated reversal of antibacterial activity. , 2014, International journal of antimicrobial agents.

[21]  N. Osheroff,et al.  Mechanism of Quinolone Action and Resistance , 2014, Biochemistry.

[22]  M. Faramarzi,et al.  Mannich bases of 7-piperazinylquinolones and kojic acid derivatives: synthesis, in vitro antibacterial activity and in silico study. , 2013, European journal of medicinal chemistry.

[23]  Rajnish Kumar,et al.  Synthesis, antibacterial evaluation and QSAR studies of 7-[4-(5-aryl-1,3,4-oxadiazole-2-yl)piperazinyl] quinolone derivatives. , 2011, European journal of medicinal chemistry.

[24]  Y. Timsit.  Local sensing of global DNA topology: from crossover geometry to type II topoisomerase processivity , 2011, Nucleic acids research.

[25]  Xilin Zhao,et al.  Quinolones: Action and Resistance Updated , 2009, Current Topics in Medicinal Chemistry.

[26]  A. Shafiee,et al.  Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. , 2009, European journal of medicinal chemistry.

[27]  Salman A. Khan,et al.  Synthesis, structure elucidation and antibacterial evaluation of new steroidal -5-en-7-thiazoloquinoxaline derivatives. , 2008, European journal of medicinal chemistry.

[28]  Yifan Liu,et al.  A Facile Total Synthesis of Imatinib Base and Its Analogues , 2008 .

[29]  M. Faramarzi,et al.  Synthesis and Antibacterial Activity of Quinolone‐Based Compounds Containing a Coumarin Moiety , 2008, Archiv der Pharmazie.

[30]  M. Faramarzi,et al.  Synthesis and Antibacterial Activity of New N-[2-(Thiophen-3-yl)ethyl]piperazinyl Quinolones. , 2007 .

[31]  A. Shafiee,et al.  Structural features of new quinolones and relationship to antibacterial activity against Gram-positive bacteria. , 2006, Mini reviews in medicinal chemistry.

[32]  B. Thiers.  Methicillin-Resistant Staphylococcus Aureus Disease in Three Communities , 2005 .

[33]  D. Talan,et al.  Methicillin-resistant Staphylococcus aureus in Community-acquired Skin Infections , 2005, Emerging infectious diseases.

[34]  H. Chambers,et al.  Community-associated MRSA--resistance and virulence converge. , 2005, The New England journal of medicine.

[35]  E. Charlebois,et al.  High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. , 2005, Annals of emergency medicine.

[36]  L. Peterson.  Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  T. Dougherty,et al.  New quinolones and the impact on resistance. , 2001, Drug discovery today.

[38]  Y. Tsuda,et al.  Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship. , 2000, Chemical & pharmaceutical bulletin.

[39]  R. Pinner,et al.  Trends in infectious disease mortality in the United States during the 20th century. , 1999, JAMA.

[40]  J. Domagala.  Structure-activity and structure-side-effect relationships for the quinolone antibacterials. , 1994, The Journal of antimicrobial chemotherapy.

[41]  K. Akahane,et al.  Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites , 1989, Antimicrobial Agents and Chemotherapy.

[42]  Lian-Shun Feng,et al.  4-Quinolone derivatives and their activities against Gram positive pathogens. , 2018, European journal of medicinal chemistry.

[43]  E. Bruno.  Methicillin-Resistant S. aureus Infections among Patients in the Emergency DepartmentMoran GJ Moran GJ, for the EMERGEncy ID Net Study Group (Olive View-UCLA Med Ctr, Sylmar, Calif; Ctrs for Disease Control and Prevention, Atlanta, Ga) N Engl J Med 355:666–674, 2006§ , 2008 .

[44]  J. A. Andrews,et al.  Linezolid resistance in clinical isolates of Staphylococcus aureus. , 2003, The Journal of antimicrobial chemotherapy.